Is cardiac resynchronization therapy an option in heart failure patients with preserved ejection fraction?

Erwan Donal1, Lars Lund, Cecilia Linde

  • 1Service de cardiologie et CIT-IC 804, LTSI Inserm U642, hôpital Pontchaillou-CHU, 35033 Rennes, France. erwan.donal@chu-rennes.fr

Insights

Electrical and mechanical dyssynchrony may affect patients with heart failure with preserved ejection fraction (HFPEF). The KaRen registry will investigate the prevalence and prognostic impact of dyssynchrony in HFPEF.

Area of Science:

  • Cardiology
  • Heart Failure Research
  • Clinical Trials

Background:

  • Electrical and mechanical dyssynchrony is known in heart failure with reduced ejection fraction.
  • Heart failure with preserved ejection fraction (HFPEF) affects up to 50% of chronic heart failure patients.
  • Limited studies suggest dyssynchrony may also occur in HFPEF, but require validation.

Purpose of the Study:

  • To investigate the prevalence of electrical or mechanical dyssynchrony in HFPEF patients.
  • To determine the prognostic impact of dyssynchrony on outcomes in HFPEF.
  • To explore dyssynchrony as a potential target for cardiac resynchronization therapy in HFPEF.

Main Methods:

  • The KaRen registry is a prospective, multicentre, international, observational study.
  • Patients are enrolled during acute congestive episodes and diagnosed with HFPEF.
  • Evaluations include clinical assessment, natriuretic peptides, ECG, and Doppler echocardiography, with follow-up for 18 months.

Main Results:

  • This section is to be filled after study completion.

Conclusions:

  • This section is to be filled after study completion.

Related Concept Videos

Heart Failure VI: Adjunct Therapies01:22

Heart Failure VI: Adjunct Therapies

Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
Cardiomyopathy V: Interprofessional Care01:29

Cardiomyopathy V: Interprofessional Care

Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
Cardiomyopathy II: Dilated Cardiomyopathy01:30

Cardiomyopathy II: Dilated Cardiomyopathy

Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
Heart Failure IV: Classification and Diagnostic Evaluation01:30

Heart Failure IV: Classification and Diagnostic Evaluation

Heart failure can be classified in various ways, with the most common classifications based on physical activity limitations, disease progression, severity, and treatment strategies.The Functional Classification of Heart Failure divides patients into four categories based on physical activity limitation due to symptom burden.Class I: Patients in this class have cardiac disease but no physical activity limitations. Ordinary activities like walking, climbing stairs, or routine tasks do not cause...